{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [],
  "article_type": "review",
  "arxiv": null,
  "author_total": 0,
  "authors": [],
  "bibtex": "https://research.draconitic.com/paper/aw9z9tjpzaztc.bib",
  "cited_by": 0,
  "doi": null,
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/books/NBK625377",
  "id": "aw9z9tjpzaztc",
  "issns": [],
  "landing_url": "https://europepmc.org/article/MED/42899951",
  "language": "eng",
  "licence": "unknown",
  "licence_label": "Licence not stated",
  "licence_source": "unknown",
  "licence_url": null,
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": "42899951",
  "published": "2026-09-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/aw9z9tjpzaztc.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:18Z",
      "native_id": "MED:42899951",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42899951"
    }
  ],
  "subjects": [],
  "title": "Pembrolizumab (Keytruda): Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy: Reimbursement Recommendation",
  "title_text": "Pembrolizumab (Keytruda): Indication: Pembrolizumab, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with MIBC who are ineligible for cisplatin-containing chemotherapy: Reimbursement Recommendation",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:18Z",
  "url": "https://research.draconitic.com/paper/aw9z9tjpzaztc",
  "venue": null,
  "versions": []
}